US Exchange Filings

60 Degrees Pharmaceuticals Appeals Nasdaq Delisting, Plans Another Reverse Stock Split

60 Degrees Pharmaceuticals faces delisting from Nasdaq after its shares remained below the exchange’s $1 minimum bid-price requirement for 30 consecutive business days. The company has appealed the decision and plans another reverse stock split, which it intends to include in its case for staying listed.

The appeal pauses any trading suspension and delisting paperwork while a Nasdaq hearings panel considers the company’s request. A further reverse split is expected to take effect on December 2, but its ratio has not yet been announced.

Key details

  • Nasdaq’s delisting decision: The company’s closing share price was below $1 from October 8 through November 18, triggering a violation of Nasdaq’s minimum bid-price rule.

  • No standard compliance period: The company completed reverse stock splits of 1-for-5 in February 2025 and 1-for-4 in January 2026—a cumulative 1-for-20 ratio. Because it has already carried out a reverse split within the past year, Nasdaq says it is not eligible for the usual period to regain compliance.

  • Appeal filed: 60 Degrees requested a hearing before a Nasdaq panel and paid a $20,000 fee. The request stays the planned trading suspension and the filing that would remove the company’s securities from Nasdaq while the panel reviews the case. The company must present a plan to regain compliance; it intends to include the new reverse split.

  • Another reverse split planned: The company expects to complete a reverse split of its issued and outstanding common stock on December 2, 2026. It says the purpose is to raise the per-share bid price. The split ratio and treatment of fractional shares have not yet been provided.

  • Trading plans: The company anticipates that its common stock will continue trading on Nasdaq under the symbol SXTP, on a split-adjusted basis, starting December 2, with a new CUSIP number.

What changes—and what remains uncertain

A reverse split reduces the number of shares outstanding and proportionally increases the share price at the time of the split; it does not, by itself, increase the company’s overall market value. The planned split is intended to address Nasdaq’s price requirement, but the company says there is no assurance the split will occur as expected, that the share price will remain high enough to meet the rule, or that the panel will allow the company to stay listed.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.